Fluticasone and mometasone have long half-lives and may be best choice for QD dosing
Prolonged use of potent fluorinated topical steroids increase risk for skin atrophy, telangiectasias, acne, particularly on face, axilla, inguinal areas
A gram of topical cream or ointment should cover a 10 × 10-cm area
A 30-60 g tube will cover the entire body of an adult once
FDA approval of topical steroids for children:
Topical Corticosteroids by Structural Class
Structural class
Class A: Hydrocortisone type
Class B: Triamcinolone acetonide type
Class C: Betamethasone type
Class D1: Betamethasone dipropionate type
Class D2: Methylprednisolone aceponate type
Cross-reactions
Cross-reacts with D2
Budesonide specifically cross-reacts with D2
Cross-reacts with class A and budesonide
Patch Test Substance
Tixocortol-21-pivalate
Budesonide Triamcinolone acetonide
Clobetasol-17-propionate
Hydrocortisone-
17-butyrate
Class 1 Superpotent
Betamethasone dipropionate (Diprolene 0.05% G, O, L)
Clobetasol propionate (Clobex Cormax, Dermovate, Temovate C, O, G, S Olux foam 0.05%)
Diflorasone diacetate (Psorcon 0.05% O)
Class 2 Potent
Amcinonide (Cyclocort 0.1% O, L, C)
Budesonide (Naricort 0.025% C)
Fluocinonide (Lidex 0.05% C, O, G, S)
Halcinonide
(Halog 0.1% C, O, S)
Desoximetasone (Topicort 0.25% C, 0.05% G)
Betamethasone dipropionate (Diprosone, Maxivate 0.05% O, Diprolene AF 0.05% C)
Tacrolimus 0.1% (Protopic) oint BID, 30, 60, 100 g
TCI Malignancy Risk
AAAAI/ACAAI Joint Task Force: “None of the information provided for the cases of lymphoma associated with the use of topical pimecrolimus or tacrolimus in AD indicate or suggest a causal relationship.”
FDA guidance regarding risk of malignancy with topical calcineurin inhibitors:
Use only as 2nd line in patients unresponsive/intolerant of other treatments
Avoid in children <2 years old; clinical studies have found higher rates of URIs in children <2 who were treated with pimecrolimus (Elidel).
Use for short periods of time and with minimum amount necessary; avoid continuous use.
Avoid in immunocompromised patients
Topical Anti-MRSA
Bactroban (mupirocin 2%) topical ointment, TID up to 12 days for impetigo, 15, 22, 30g
Bactroban nasal (mupirocin calcium 2%) ointment indicated for treatment of nasal MRSA carriers, 0.5 g intranasal BID x 5 days, supplied as 10-pack of 1 g tubes
Altabax (retapamulin 1%) topical ointment, BID x 5 days for impetigo, 5, 10, 15g
Table of Contents
Topical Corticosteroids by Potency
(I—MOST POTENT, VII—LEAST POTENT)German Classification System
Notes
Topical Corticosteroids by Structural Class
Hydrocortisone type
Triamcinolone acetonide type
Betamethasone type
Betamethasone dipropionate type
Methylprednisolone aceponate type
17-butyrate
Superpotent
Potent
(Halog 0.1% C, O, S)
(Elocon 0.1% O)
Lower mid-strength
Mild
Tridesilon 0.05% C)
(Derma-Smoothe, Synalar
0.01% C, Sol)
(Aristocort, Kenalog 0.025% C)
(Amcort, Aristocort 0.025% C)
(Aclovate 0.05% C, O)
Least potent
Topical Calcineurin Inhibitors (TCIs)
TCI Malignancy Risk
Topical Anti-MRSA
References